Latest Healthcare News

Pro Medicus Limited’s U.S. subsidiary has landed a $25 million, seven-year contract to deploy its cloud-based Visage 7 Open Archive with BayCare, extending an existing partnership and marking a significant step in its North American growth.

Papyrus Australia reported a $112k net operating cash outflow in October 2025, offset by financing activities and R&D tax incentives, maintaining a runway of over five months. Despite a non-recurring legal expense and an investment write-down, the company remains confident in its operational continuity.

BTC Health has broadened its medical product portfolio through strategic acquisitions and organic growth, reporting strong early revenue gains while cautiously navigating the uncertain timing of ECMO system adoption.

Singular Health has submitted a 510(k) premarket notification to the FDA for its enhanced 3DICOM MD Cloud platform, aiming to expand imaging capabilities and introduce a scalable, cloud-native solution for medical image management.

Cann Group Limited has announced a dramatic 81% reduction in core debt alongside a strategic pivot to higher-margin flower products, positioning the company for its first EBITDA-positive year in FY26.

Cann Group Limited has successfully restructured its debt, stabilizing its finances and boosting operational performance, while appointing Mike Ryan as its new Chairman to guide future growth.

BTC Health has raised $2 million through a share placement priced at a slight premium, with director Martin Kahanovitz participating and a new South African investor joining the register.

TruScreen Group Limited reported a 17% decline in first half FY2026 product sales but affirmed full-year revenue guidance at NZ$2.8 million, supported by strategic expansions and a successful NZ$4 million capital raise.

Amplia Therapeutics reported a $4.18 million half-year loss but bolstered its cash reserves with a $27.6 million capital raise to advance clinical trials of its lead drug narmafotinib, showing encouraging interim data in pancreatic cancer.

Uscom Limited reported a 25% revenue decline in FY25 amid global geopolitical challenges but reinforced its commitment to growth through strategic partnerships and innovative medical technologies.

Hexima Limited reveals plans to return capital to shareholders and restructure its board following the closure of its main clinical program and prolonged ASX trading suspension.

SomnoMed Limited reported a robust FY25 with revenue surpassing guidance and a landmark FDA clearance for its Rest Assure® oral device, setting the stage for sustained growth in oral appliance therapy.